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Abstract
Introduction: Skeletal metastases from breast adenocarcinoma are responsible for most of the morbidity and
mortality associated with this tumor and represent a significant and unmet need for therapy. The arrival of
circulating cancer cells to the skeleton depends first on the adhesive interactions with the endothelial cells lining
the bone marrow sinusoids, and then the extravasation toward chemoattractant molecules produced by the
surrounding bone stroma.
We have previously shown that the membrane-bound and cell-adhesive form of the chemokine fractalkine is
exposed on the luminal side of human bone marrow endothelial cells and that bone stromal cells release the
soluble and chemoattractant form of this chemokine. The goal of this study was to determine the role of
fractalkine and its specific receptor CX3CR1 in the homing of circulating breast cancer cells to the skeleton.
Methods: We employed a powerful pre-clinical animal model of hematogenous metastasis, in which fluorescent
cancer cells are identified immediately after their arrival to the bone. We engineered cells to over-express either
wild-type or functional mutants of CX3CR1 as well as employed transgenic mice knockout for fractalkine.
Results: CX3CR1 protein is detected in human tissue microarrays of normal and malignant mammary glands. We
also found that breast cancer cells expressing high levels of this receptor have a higher propensity to spread to
the skeleton. Furthermore, studies with fractalkine-null transgenic mice indicate that the ablation of the adhesive
and chemotactic ligand of CX3CR1 dramatically impairs the skeletal dissemination of circulating cancer cells. Finally,
we conclusively confirmed the crucial role of CX3CR1 on breast cancer cells for both adhesion to bone marrow
endothelium and extravasation into the bone stroma.
Conclusions: We provide compelling evidence that the functional interactions between fractalkine produced by
both the endothelial and stromal cells of bone marrow and the CX3CR1 receptor on breast cancer cells are
determinant in the arrest and initial lodging needed for skeletal dissemination.
Introduction
Currently, only six percent of women that are first diag-
nosed with breast adenocarcinoma present with metas-
tases [1]. Unfortunately, between 20 and 50% of them
will eventually develop a metastatic disease [1]. Metas-
tases are responsible for an intolerably high number of
deaths among patients that would otherwise be almost
invariably cured by surgical resection and adjuvant ther-
apy [2]. Autopsy studies have estimated that 70% of
advanced breast cancer patients have skeletal metastases
[3]. These secondary bone tumors are a major cause of
lethality and are also responsible for significant morbid-
ity, leading to considerable pain, spinal cord compres-
sion and pathological fractures [4].
Metastases are caused by cancer cells disseminated to
secondary tissues during different stages of primary
tumor progression and often remained dormant for vari-
able periods of time [5,6]. However, metastatic dissemi-
nation could take place also after primary therapeutic
intervention and can be caused by cancer cells departing
from either residual tumor or recurrences. For instance,
the detection of positive surgical margins upon resection
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related to the incidence of tumor recurrence [1,7,8].
Prior to re-intervention, residual cancer cells in patients
with positive resection margins may benefit from a fer-
tile stromal environment that promotes dissemination
[9]. This process would produce secondary waves of
micrometastases with - at least - equal probability of
developing into macroscopic tumors as those seeded
years earlier. Thus, the adoption of adjuvant measures
aimed to interfere with the arrival of cancer cells to the
skeleton would protect breast cancer patients from post-
surgery tumor dissemination.
The arrest of circulating cancer cells to the skeleton is
highly dependent on specific adhesive interactions with
the endothelial cells lining the marrow sinusoids
[10-12]. The required next step is the extravasation of
adherent cancer cells drawn by chemo attractant cues
generated by the surrounding stroma [13]. The similari-
ties between cancer cell dissemination and leukocyte
trafficking lead to the identification of chemokines as
crucial players in both sets of events [14]. The chemo-
kine CX3CL1 (Fractalkine or FKN, which will be used
throughout the rest of the manuscript) exists as a trans-
membrane protein that is cleaved into a soluble mole-
cule with potent chemoattractant properties [15]. In its
membrane-bound form, FKN can establish strong and
stable adhesive interactions with its receptor CX3CR1.
In contrast to other chemokines, adhesion through FKN
does not require activation of additional adhesion mole-
cules via intracellular signaling pathways [16-18].
Because of its unique structural and functional proper-
ties, FKN is an ideal candidate to mediate both adhesion
and extravasation of CX3CR1-bearing circulating cancer
cells.
We were the first to report that prostate cancer cells
express CX3CR1 and that these cells, under dynamic-
flow conditions, adhere to human bone marrow
endothelial cells in a FKN-dependent manner [19]. In
addition, we have shown that CX3CR1 is expressed in a
high percentage of prostate cancer tissues while human
bone marrow supernatants contain soluble FKN, which
is released from cells of the bone stroma through a
mechanism regulated by androgens [20].
Here we show that both normal and malignant breast
tissues express CX3CR1 and the ability of breast cancer
cells to lodge in the skeleton of animal models is
increased by the over-expression of CX3CR1. Remark-
ably, when breast cancer cells were inoculated in trans-
genic mice knockout for FKN (FKN
-/-)v i aa
hematogeneous route, a 70% reduction in the detection
of bone disseminated tumor cells (DTC) was observed
as compared to FKN-expressing animals. Finally, by
using functional mutants of CX3CR1 we provide
evidence that this receptor regulates both adhesion and
extravasation of breast cancer cells.
Materials and methods
Cell lines and cell cultures
MDA-MB-231 (MDA-231) and MDA-MB-436 (MDA-
436) human breast cancer cells were purchased from
ATCC (Manassas, VA, USA). All cells were grown in
DMEM containing 10% fetal bovine serum (Hyclone,
Logan, UT, USA) and 0.1% gentamicin (Invitrogen,
Carlsbad, CA, USA) and kept at 37°C and 5% CO2.F o r
the experiments performed in vivo, cells were engi-
neered to stably express enhanced Green Fluorescent
Protein (eGFP) using a lentiviral vector from America
Pharma Source (Bethesda, MD, USA). Transduced cells
were enriched for eGFP expression by flow cytometry
and sorting.
Transfection and selection of stable cell lines
The cDNAs for wild-type and mutant CX3CR1 isoforms
were inserted in the pEGFP-N1 vector (Clontech, Inc.,
Mountain View, CA, USA). MDA-436 cells were trans-
fected with 3 μg of plasmid DNA using the Lipofecta-
mine 2000 transfection system according to the
manufacturer’s instructions (Invitrogen). Stable trans-
fected cells were selected using geneticin (Invitrogen).
Immunohistochemistry and tissue array analysis
Three different breast tissue microarrays (BRC1502,
BR1002 and BR722) were obtained from US Biomax
(Rockville, MD, USA) and included 202 tissue cores of
breast cancer and 47 cores of normal breast tissue. The
staining for CX3CR1 was performed as described pre-
viously [20], using an antibody against CX3CR1 (7201)
obtained from Abcam (Cambridge, MA, USA) and used
at a 3.3 μg/ml concentration. Negative controls were
obtained by omitting the primary antibody.
Animal models of metastasis
Five week-old female CB17-SCID, C57Bl/6 and Balb/c
mice were obtained from Taconic (Germantown, NY,
USA) and housed in a germ-free barrier. C57Bl/6-
FKN
-/- transgenic mice were obtained from Dr. Sergio
Lira (Mount Sinai School of Medicine, NY, USA) and
Schering-Plough (now Merck-Schering Plough, White-
house Station, NJ, USA) and bred in-house. C57BI/6
mice were used as same-strain controls for the C57Bl/6-
FKN
-/- transgenic mice to detect cancer cells dissemi-
nated to the skeleton at 24 hours post-inoculation. The
engrafting of human cancer cells is conventionally con-
ducted using immune-compromised mice and aims to
avoid the elimination of the xenogeneic human cells by
the immune system of the recipient animal.
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extent of bone dissemination observed in Balb/C, SCID
or C57BI/6 examined at 24 hours post cell-inoculation.
This indicates that, within this time frame, the fully
competent immune system of Balb/C and C57BI/6 mice
is unable to affect the survival of human cells grafted in
the blood circulation. However, we considered that the
possibility for an acute humoral xenograft rejection
(AHXR) between 24 and 72 hours post-inoculation of
human cancer cells was substantial. While T- and B-
lymphocytes are strongly implicated in the establishment
of AHXR [21], SCID mice have fully functional NK cells
and macrophages but lack T- and B-lymphocytes [22].
Thus, these animals were used for the experiments mea-
s u r i n gt h en u m b e ro fb o n eD T C sa t7 2h o u r sp o s t -
inoculation.
At six to eight weeks of age, mice were anesthetized
with the combined administration of ketamine (80 mg/
kg) and xylazine (10 mg/kg) administered by intraperito-
neal route and then inoculated in the left cardiac ventri-
cle with either MDA-436 or MDA-231 human cancer
cells. Cell inoculation was performed using an insulin
syringe with a 30-gauge needle. The correct execution
of intracardiac inoculation was established by the
appearance of fresh arterial blood in the Luer-Lok fitting
of the hypodermic needle, which indicated the success-
ful penetration of the ventricular wall. In addition, blue-
fluorescent polystyrene beads (10 μm diameter, Invitro-
gen-Molecular Probes) were co-injected with cancer
cells. Their detection by fluorescence microscopy in dif-
ferent organs at necropsy confirmed the successful
inoculation in the blood circulation.
We found that MDA-436 cells are much less effective
in disseminating to the skeleton as compared to MDA-
231 cells. Thus, for the experiments comparing meta-
static dissemination of MDA-436 and MDA-231 cells or
in which MDA-436 cells expressing either wild-type
CX3CR1 or one of its functional mutants were inoculated
alone, we used 5 × 10
5 cells in a total volume of 200 μlo f
DMEM/F12. However, for the experiments comparing
the number of DTCs in FKN-expressing and FKN(-/-)
mice, we inoculated only 1 × 10
5 MDA-231 cells.
All experiments were performed in accordance with
NIH guidelines for the humane use of animals. All pro-
tocols involving the use of animals were approved by
the Drexel University College of Medicine Committee
for the Use and Care of Animals.
Tissue preparation and cancer cell detection
Animals were sacrificed and tissues were fixed, decalci-
fied in 0.5 M EDTA if necessary and frozen in O.C.T.
embedding medium (Electron Microscopy Sciences,
Hatfield, PA, USA) as previously described [23]. Serial
tissue sections of 80 μm in thickness were obtained
using a Microm HM550 cryostat (Mikron, San Marcos,
CA, USA). Sections of each hind leg and soft-tissue
organs were transferred on glass slides, stored at -20°C
and examined for cancer cells using either an Olympus
IX70 fluorescence inverted microscope or an Olympus
SZX12 fluorescence stereomicroscope. Bright field and
fluorescence images were acquired with an Olympus
DT70 CCD color camera.
Detection of soluble FKN in murine bone marrow
Bone marrow was flushed from the hind legs of wild-
type C57Bl/6 mice or FKN-null mice. The cellular frac-
tion was removed by centrifugation at 2,000 r.p.m. for
10 minutes at 4°C. Soluble FKN was detected using an
ELISA DuoSet kit for murine FKN (R&D Systems, Min-
neapolis, MN, USA) as previously described [20].
CX3CR1 signaling in vitro
Cells were serum starved for four hours and then
exposed to 50 nM recombinant human FKN (R&D Sys-
tems) for indicated time points.
Cell surface CX3CR1 protein isolation
The amount of either wild-type or functional mutant
forms of CX3C R 1t h a tw e r ee x p r e s s e db yM D A - 4 3 6
breast cancer cells at the plasma membrane level were
measured by cell surface biotinylation, using a dedicated
kit (cat. #89881) obtained from Pierce (Rockford, IL,
USA) and according to the protocol provided by the
manufacturer.
SDS-PAGE and Western blotting
Cell lysates were obtained and SDS-polyacrylamide gel
electrophoresis and Western blot analysis were performed
as previously described [19], with few modifications. Mem-
branes were probed with an antibody against CX3CR1 (0.5
μg/ml, Torrey Pines Biolabs, East Orange, NJ, USA) using
5% milk as a blocking reagent. Membranes were also
probed with antibodies targeting phospho-p44/42 MAPK
(Thr202/Tyr204, Cell Signaling, Beverly, MA, USA) and
total p44/42 MAPK (Cell Signaling). Normalization of gel
loading was achieved by using an antibody for beta-actin
(Sigma, St. Louis, MO, USA). All primary antibody incuba-
tions were performed overnight at 4°C. Primary antibody
binding was detected using horseradish peroxidase-conju-
gated anti-rabbit secondary antibody (Pierce). Chemilumi-
nescent signals were obtained using SuperSignal West
Femto reagents (Pierce) and detected with the Fluorochem
8900 imaging system and relative software (Alpha Inno-
tech, San Leandro, CA, USA).
Statistics
Statistical significance for the in vivo studies was deter-
mined using a one-tailed Student’s t-test using
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Diego, CA, USA) and data are presented as mean ±
standard error of the mean (S.E.M.). The significance of
CX3C R 1s t a i n i n go fT M A sw a se s t a b l i s h e db yat w o -
tailed Fisher’s exact test performed using GraphPad
Prism and using the method of summing small P-values.
Results and discussion
This study was based on the working hypothesis that
specific interactions between the receptor CX3CR1 and
its chemokine ligand FKN are responsible for the arrival
and lodging of circulating breast cancer cells to the
skeleton.
To ascertain whether human breast expresses the che-
mokine receptor, we processed human tissue microar-
rays of normal and malignant mammary glands for
CX3CR1 detection by immunohistochemistry. As shown
by Figure 1, both normal and tumor tissues stained dif-
fusely for CX3CR1 and the signal was strictly limited to
the epithelial compartment. However, 26% of malignant
A B 
C D 
E  F 
Figure 1 Expression of CX3CR1 in human breast cancer tissue arrays.P a n e lA shows a representative sample that stained negative for
CX3CR1. The majority of samples examined showed different degrees of positive staining for the receptor in the epithelial cells (B-D; see also
Table 1). Panels E and F show a negative and highly positive sample for CX3CR1, respectively, at higher magnification. The stromal compartment
stained uniformly negative for CX3CR1. Representative images of 47 normal and 202 malignant tissue cores analyzed. (Original magnification
×100 for A to D and ×200 for E and F).
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staining intensity observed and broad signal distribution:
only 1 out of 47 samples of normal mammary tissue
demonstrated this similar staining pattern (Table 1).
Thus, the CX3CR1 chemokine receptor is frequently
detected in normal mammary glands where its expres-
sion and distribution increases with malignant transfor-
mation. This scenario closely resembles what we
previously described for human prostate tissue [20]. Our
previous studies with human prostate cancer cell lines
also revealed that the CX3CR1-FKN pair mediates both
the adhesion of cancer cells to endothelial cells of the
bone marrow under dynamic-flow conditions and their
migration following chemoattractant gradients in vitro
[19]. These events are crucial to ensure the arrest and
lodging of cancer cells departing from the primary
tumor and arriving to the skeleton through the hemato-
genous route. Because of the strong propensity to disse-
minate and grow in the bone shown by breast
adenocarcinoma, we asked whether a correlation could
be found between the levels of CX3CR1 expression and
bone-metastatic potential of human breast cancer cell
lines. Thus, we selected MDA-231 cells, which are
widely recognized as strongly bone-metastatic [24-26],
and MDA-436 cells for which the ability to effectively
target the skeleton and grow into macroscopic metas-
tases in animal models has never been reported. When
these two cell lines were tested for CX3CR1 by Western
blotting, MDA-231 cells were found positive whereas
MDA-436 express minimal levels of this receptor (Fig-
ure 2A). To investigate whether this disparity in
CX3CR1 expression could account for a different ability
to arrest at the skeleton, we tested these two breast can-
cer cell lines by delivering them into the blood circula-
tion of mice. As previously described, we have
established an animal model of metastatic dissemination
that allows the identification of single cancer cells
immediately after their arrival to different tissues,
including the bone [23]. We have also shown that pros-
tate cancer cells delivered into the arterial blood circula-
tion consistently lodge at the metaphysis of the distal
femur and proximal tibia of inoculated animals
[23,27-29]. Using a similar approach for this study, mice
were inoculated via the left cardiac ventricle with MDA-
231 or MD-436 cells that stably expressed eGFP and
sacrificed 24 hours later. Tibiae and femora of each
m o u s ew e r ec o l l e c t e d ,p r o c e ssed for cryosectioning and
found to be harboring cancer cells when inspected by
fluorescence microscopy. DTC were identified and
counted throughout each entire bone by analyzing all
serial sections obtained. These experiments revealed a
much stronger propensity of MDA-231 cells to home to
the bone marrow than MDA-436 cells (Figure 2B, C).
The three-fold higher number of MDA-231 cells
detected in the bone of inoculated mice correlates with
the higher expression of CX3CR1 detected in these cells
as compared to MDA-436 cells. However, more causal
evidence for the role exerted by the CX3CR1-FKN pair
in breast cancer cell homing to the bone would require
interfering with the molecular interactions between the
chemokine and its receptor in vivo. This opportunity
was offered by a FKN-null transgenic mouse previously
generated by Dr. Lira and collaborators [30]. So far, this
approach could not be pursued to test the role in metas-
tasis of other chemokines, such as CXCL12/SDF1, since
CXCL12-null transgenic mice are not viable. In contrast,
besides surviving targeted gene-disruption, FKN-null
mice do not exhibit overt behavioral abnormalities or
macroscopic anatomical alterations. The CX3CR1-FKN
pair is involved in leukocyte trafficking and immune
response in general; an in-depth analysis of these ani-
mals revealed that the responses to inflammatory stimuli
were comparable to those of C57Bl/6 wild-type mice.
We used an ELISA-based assay and confirmed the
a b s e n c eo ft h es o l u b l ec h e m o k i n ei nt h eb o n em a r r o w
of FKN(-/-) mice, which, in contrast, was detected in
the parental C57Bl/6 mouse strain at an average con-
centration of 6.4 ng/ml. FKN(-/-) mice inoculated with
CX3CR1-expressing MDA-231 cells displayed a dramatic
reduction of more than 70% in the number of breast
DTC detected 24 hours later in the bone marrow of
tibia and femur, as compared to wild-type animals (Fig-
ure 3). As a small number of DTC were still detected in
the bone of FKN(-/-) mice, it is plausible that additional
molecules are implicated in the homing of these breast
cancer cells to the skeleton. However, the dramatic
reduction of bone DTC upon ablation of FKN indicates
that CX3CR1 expression should be considered an
important feature of breast cancer cells with bone-meta-
static potential. Interestingly, we observed no differences
between wild-type and FKN(-/-) mice in the number of
MDA-231 cells detected in the adrenal glands, which
are soft-tissue organs that can be also moderately colo-
nized in our animal model (Figure 4). This rules out the
possibility that the targeted ablation of FKN could non-
Table 1 Intensity and distribution of CX3CR1 in normal
and malignant breast tissues
Tissues 0 0 to 1 1 to 2 2 to 3 Total
Normal 21 (45%) 19 (40%) 6 (13%) 1 (2%) 47
Malignant 43 (21%) 54 (27%) 53 (26%) 52 (26%) 202
Staining intensity was scored based on a scale in which negative specimens
were graded (0) and strongly positive samples were graded (3). To evaluate
distribution, tissues with complete lack of staining were scored as (0); tissues
prevalently negative for CX3CR1 displaying some areas of positive staining
were scored as (0 to 1); tissues showing uniform staining for CX3CR1 were
scored as either (1 to 2) or (2 to 3), based on the intensity of the signal
observed. The increase in CX3CR1 expression observed in cancer samples as
compared to normal samples resulted to be statistically significant with a P-
value equal to 0.0016.
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culation and reinforces the specificity of the CX3CR1-
FKN pair in regulating the migration of cancer cell to
the skeleton.
In light of the in vivo results provided by the FKN(-/-)
mouse model, we decided to further investigate the
involvement of CX3CR1 in breast cancer metastasis by
exogenously expressing this receptor in MDA-436 cells,
as we found that these cells do not express CX3CR1 and
migrate to the bone with very low efficacy (Figure 2). In
addition, we sought to further dissect the relative impact
that CX3CR1 exerts in adhesion to the endothelium of
MDA-436
MDA-231 B
MDA      MDA  
231 436         THP-1  
CX3CR1
Actin
C
A
*
Figure 2 Expression of CX3CR1 by human breast cancer cells. Western blotting analysis of CX3CR1 expression in MDA-231 and MDA-436
breast cancer cell lines. CX3CR1 was detected in MDA-231 cells, whereas MDA-436 showed negligible levels of the receptor. The two bands
observed are likely due to the detection of different isoforms of the receptor produced by alternative splicing [33]. Cell lysates from the THP-1
human monocytic cell line were included as a positive control. Actin was used as a loading control (A); single breast cancer cells stably
expressing eGFP (arrows) were identified by fluorescence stereomicroscopy in the bone marrow of mice, 24 hours after being inoculated via the
left cardiac ventricle (B); MDA-231 and MDA-436 cell lines that migrated to the femora and tibiae of mice inoculated via the hematogenous
route, expressed as mean of cells detected per animal + S.E.M. (C). (MDA-231 cells = four mice, MDA-436 cells = eight mice. * P = 0.0008).
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bone marrow stroma, respectively. We have previously
reported that both adhesion and migration of prostate
cancer cells can be regulated by FKN in vitro [19]. How-
ever, the targeted deletion of this chemokine eliminates
both the trans-membrane adhesive molecule and the
soluble chemoattractant form, and therefore the FKN
(-/-) mice could not be used to address this specific
issue. The next series of experiments were, therefore,
conducted with MDA-436 cells stably expressing either
the wild-type form of CX3CR1 or one of the two follow-
ing functional mutants of this receptor. The first mutant
was generated by introducing a tyrosine to phenylala-
nine mutation at amino acid 14 of the first extracellular
domain of CX3CR1 (Y14F) [31]. This mutant was
previously characterized for its failure to firmly bind to
FKN, most likely because of the inability of phenylala-
nine to be sulfated, a modification that enhances the
binding to this chemokine. Although defective in cap-
ture and adhesion, CX3CR1 (Y14F) is competent in sig-
nal transduction, but with a 100-fold decreased affinity
to immobilized FKN [31]. The specific involvement of
CX3CR1 in extravasation was evaluated using a second
functional mutant containing an arginine to asparagine
mutation at amino acid 128, which is located in the sec-
ond intracellular loop of CX3CR1 and in the highly con-
served aspartic acid-arginine-tyrosine (DRY) sequence of
G-protein coupled receptors [16]. Chemoattractant
properties of chemokine receptors are dependent on G-
protein activation and subsequent ability to transduce
downstream signals following stimulation by the appro-
priate ligand [32]. As the DRY sequence is required for
G-protein activation, the R-to-N mutation makes the
**
C57BI/6 C57BI/6
FKN KO
CB I / 6 C BI/6
Figure 3 Reduced homing of CX3CR1-expressing cancer cells in
the bone of FKN-null mice. The number of MDA-231 cells
detected in the skeleton of transgenic FKN(-/-) mice (n =5 )2 4
hours after intra-cardiac inoculation is significantly decreased
compared to the number of cells detected in wild-type C56BI/6
mice (n = 4). The number of cells detected in the femora and tibiae
per animal is shown as mean + S.E.M. (**-P = 0.0002).
A
B
THP-1
CX3CR1
Actin
CX3CR1
TOTAL
CELL LYSATE
CELL SURFACE
FRACTION
CYTOSOLIC
FRACTION
Actin
Figure 4 Exogenous expression of wild-type and functional
mutants of the CX3CR1 receptor in MDA-436 breast cancer
cells. Western blotting analysis of total cell lysates collected from
parental MDA-436 cells as well as cells stably overexpressing the
wild-type CX3CR1, the adhesion-impaired Y14F mutant or the
chemotaxis-impaired R128N mutant of the receptor. Actin was used
as a loading control (A); the correct insertion of each exogenously
overexpressed form of the CX3CR1 receptor at the plasma
membrane level of transfected MDA-436 cells was confirmed by
cell-surface protein isolation (B). Cell lysates from the THP-1 human
monocytic cell line were included as a positive control for CX3CR1
expression. Actin detected in the cytosolic fraction was used as a
loading control.
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cells expressing the CX3CR1 (R128N) mutant do not
migrate toward FKN, while showing normal binding/
adhesion to this chemokine [16]. The expression of
wild-type and mutated forms of CX3CR1 by MDA-436
cells was verified by western blotting performed on total
cell lysates (Figure 4A).
In addition, the insertion of each form of the receptor
at the plasma membrane level of transfected cells was
confirmed using Western blot analysis of cell surface
proteins isolated by biotinylation (Figure 4B).
When MDA-436 cells engineered to exogenously
express CX3CR1 were exposed to 50 nM soluble FKN in
vitro, a time-dependent phosphorylation of ERK1/2 was
observed. As expected, this downstream signaling was
not detected in untransfected cells, as they express
minimal levels of CX3CR1 (Figure 5). The MDA-436
cells expressing the Y14F mutant responded to soluble
FKN with a negligible and non-statistically significant
activation of the MAPK pathway, most likely as a conse-
quence of the reduced affinity for the chemokine, as dis-
cussed above. Finally, the R128N mutant did not
transduce downstream signals in MDA-436 cells, con-
firming its inability to activate G-protein (Figure 5). The
role of wild -type and functional mutants of CX3CR1 in
regulating the homing of breast cancer cells to the ske-
leton was then tested by inoculating MDA-436 cells in
mice as untransfected cells or expressing one of the
three available forms of the receptor. Animals were
sacrificed at either 24 or 72 hours following inoculation,
to allow discriminating between the fast adhesion to the
bone marrow endothelium and the relatively delayed
P - ERK
   ERK
P P  P
MDA-436 MDA-436 (CX3CR1) MDA-436 (Y14F) MDA-436 (R128N)
0      5      15     30 0      5      15     30 0      5       15    30 0      5      15     30
minutes
* *
Figure 5 Intracellular signaling of CX3CR1 and functional mutants exogenously expressed in MDA-436 cells. Western blotting analysis of
MDA-436 cells that when exposed to 50 nM of human FKN failed to phosphorylate Erk1/2, as expected from the minimal expression of
endogenous CX3CR1. Cells that were engineered to stably overexpress wild-type CX3CR1 (MDA-436+X) showed a significant and time-dependent
Erk phosphorylation in response to FKN. Finally, cells expressing the Y14F (MDA436+Y14F) or R128N (MDA436+R128N) functional mutants of the
receptor showed a negligible or lack of Erk phosphorylation, respectively; the intensity levels of Erk phosphorylation obtained from three
independent experiments were evaluated by densitometry analysis and normalized using total Erk signals after membrane stripping to
compensate for variations in protein loading among samples. Data are represented as mean ± S.E.M. (* P < 0.003).
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hours, the expression of wild-type CX3CR1 doubled the
number of MDA-436 cells detected in the bones of
inoculated mice (Figure 6A). This result provides strong
support for the role of CX3CR1 in mediating the arrival
of circulating breast cancer cells to the skeleton and
further validates the significantly higher ability for skele-
tal dissemination shown by CX3CR1-expressing MDA-
231 cells as compared to CX3CR1-negative MDA-436
cells. Cells expressing the CX3CR1(Y14F) mutant
arrested to the bone in numbers comparable to cells
lacking the receptor, a clear expression of their inability
to bind and adhere to FKN on the luminal side of bone
marrow endothelial cells. On the other hand, MDA-436
cells expressing the CX3CR1(R128N) mutant arrested to
the skeleton with an efficiency comparable to cells
expressing the wild-type receptor, indicating that extra-
vasation into the marrow stroma required longer than
24 hours from the entering of the blood circulation
(Figure 6A). When animals were examined at 72 hours
following cell inoculation, the number of MDA-436 cells
either lacking or expressing the CX3CR1 receptor that
were detected in the bone was lower than that observed
at 24 hours post-inoculation (Figure 6B). This suggests
that a significant number of adherent cells fail to extra-
vasate and are eventually dislodged from the endothelial
wall. Interestingly, even in these conditions, CX3CR1
still provided MDA-436 cells with a three-fold higher
propensity to remain at the skeleton as compared to
cells lacking this receptor. The cells expressing either
CX3CR1(Y14F) or (R128N) mutants failed to show
increased lodging in the bone as compared to cells lack-
ing CX3CR1 expression. This was plausibly due to their
inability to initially adhere to the endothelium or
migrating toward the soluble FKN produced and
released in the bone marrow by stromal cells [20],
respectively.
Taken together, these results provide definitive sup-
port to the idea that the interactions between CX3CR1
and FKN promote skeletal dissemination of circulating
breast cancer cells. Importantly, this observation might
be likely extended to other malignant phenotypes,
including those deriving from tumors of the prostate
gland [19]. In addition, the role exerted by CX3CR1 in
the arrest to the bone includes the regulation of both
cell adhesion and extravasation, in line with the ability
of this receptor to interact with both plasma membrane-
bound and soluble FKN.
Conclusions
Based on our study, it seems reasonable to propose that
the dissemination to the skeleton of breast cancer cells
can be effectively counteracted by interfering with the
molecular and functional interactions between the
chemokine FKN and its only receptor CX3CR1. The
detection of this receptor in the majority of human
breast tissue samples we examined (Table 1) suggests
that this type of strategy could protect a relevant
** *
* *
***
***
*
B
A
Figure 6 Role of CX3CR1 in the adhesion and extravasation of
breast cancer cells. The number of MDA-436 cells expressing
exogenous CX3CR1 that were detected in the femora and tibiae of mice
24 hours after intracardiac inoculation was significantly larger than that of
untransfected MDA-436 cells. The expression of the adhesion-defective
Y14F mutant of the receptor failed to increase the arrival of MDA-436
cells to the skeleton, whereas the chemotaxis-defective R128N mutant
was still able to promote arrival to bone similarly to the wild-type
CX3CR1 (A); when animals were inspected at 72 hours post-inoculation,
the difference in bone arrival between parental and CX3CR1-expressing
MDA-436 cells was even more significant than what was observed after
24 hours. Also, at this later time point, cells expressing the Y14F
adhesion-defective mutant were detected in numbers similar to the
untrasfected cells. Finally, the cells expressing the R128N mutant, despite
their ability to adhere normally to the bone marrow endothelium at 24
hours, failed to extravasate and were then detected in numbers similar
to the untransfected cells (B). Between four and seven mice were used
for the analysis of parental and different CX3CR1-expressing MDA-436
cells migrated to the skeleton at each time point. Data are reported as
mean ± S.E.M. (*-P ≤ 0.03, **-P ≤ 0.006, ***-P < 0.0001).
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Page 9 of 11number of patients from skeletal metastases. In light of
the concrete possibility of post-surgery spreading, these
results should bolster the synthesis of CX3CR1 inhibi-
tors and their pre-clinical and clinical testing, to ulti-
mately conceive new adjuvant therapeutic approaches
and promote a paradigm shift in the management of
breast cancer patients.
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